Geropharm plans to expand exports to three new countries by year's end

ST. PETERSBURG. May 14 (Interfax) - Pharmaceutical company Geropharm (Geropharm LLC, St. Petersburg) plans to begin product shipments to three new countries in 2025, CEO Pyotr Rodionov told Interfax on the sidelines of the Russian Pharmaceutical Forum in St. Petersburg.

The company currently exports medicines to 14 countries.

"We're actively working to expand our country list. We're not disclosing specific markets where registration is underway, as this constitutes sensitive information. We'll announce them upon receiving marketing authorizations. We're also developing plans to expand our product range in existing markets. We strongly anticipate export support measures currently being discussed and included in the Pharma-2030 program," Rodionov said.

Geropharm currently ships pharmaceutical products to North African and Latin American countries, he said.

Geropharm is a biotechnology company founded in 2000. In October 2013, the company launched a full-cycle plant for the production of genetically engineered human insulin in the Moscow Region, and at the end of 2018, an enterprise for the production of insulin active ingredients in St. Petersburg.

The company also includes a research and development center that develops drugs for the treatment of diabetes, including analogue insulin, as well as neurological, ophthalmological, and urological drugs.